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Background: Phyllanthus niruri L. is a well-known hepatoprotective and antiviral medicinal herb. Recently, we
identified Corilagin as a major active component with anti-tumor activity in this herbal medicine. Corilagin is a
member of the tannin family that has been discovered in many medicinal plants and has been used as an anti-
inflammatory agent. However, there have been few reports of the anti-tumor effects of Corilagin, and its anti-tumor
mechanism has not been investigated clearly. The aim of the present study is to investigate the anticancer
properties of Corilagin in ovarian cancer cells.
Methods: The ovarian cancer cell lines SKOv3ip, Hey and HO-8910PM were treated with Corilagin and analyzed by
Sulforhodamine B (SRB) cell proliferation assay, flow cytometry, and reverse phase protein array (RPPA). Corilagin
was delivered intraperitoneally to mice bearing SKOv3ip xenografts.
Results: Corilagin inhibited the growth of the ovarian cancer cell lines SKOv3ip and Hey, with IC50 values of less
than 30 μM, while displaying low toxicity against normal ovarian surface epithelium cells, with IC50 values of
approximately 160 μM. Corilagin induced cell cycle arrest at the G2/M stage and enhanced apoptosis in ovarian
cancer cells. Immunoblotting assays demonstrated that Cyclin B1, Myt1, Phospho-cdc2 and Phospho-Weel were
down-regulated after Corilagin treatment. Xenograft tumor growth was significantly lower in the Corilagin-treated
group compared with the untreated control group (P <0.05). More interestingly, Corilagin inhibited TGF-β secretion
into the culture supernatant of all tested ovarian cancer cell lines and blocked the TGF-β-induced stabilization of
Snail. In contrast, a reduction of TGF-β secretion was not observed in cancer cells treated with the cytotoxic drug
Paclitaxel, suggesting that Corilagin specifically targets TGF-β secretion. Corilagin blocked the activation of both the
canonical Smad and non-canonical ERK/AKT pathways.
Conclusions: Corilagin extracted from Phyllanthus niruri L. acts as a natural, effective therapeutic agent against the
growth of ovarian cancer cells via targeted action against the TGF-β/AKT/ERK/Smad signaling pathways.
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Ovarian cancer is the most common form of gyneco-
logic neoplasm and the fifth most common cause of
cancer mortality in women. Although there have
been improvements in surgical techniques and trea-
tment options, the five-year survival for stages IIB to
IV ovarian cancer is less than 40% [1]. The current
chemotherapeutic in common clinical use is platinum
combined with Paclitaxel, which has enhanced drug
toxicity. Therefore, researchers are searching for new
anti-ovarian cancer drugs that are eutherapeutic and
inflict fewer side effects. Work in herbal medicine is
especially highlighted.
Since 2005, we have screened hundreds of herbs,
among which Phyllanthus niruri L. has the greatest anti-
cancer potential. Phyllanthus niruri L. (P. niruri L.)
belongs to the Euphorbiaceae family and originated in
India. It usually occurs as a winter weed throughout the
tropic and subtropic parts of the globe, including China,
South Asia, and America. Our garden has introduced
and domesticated this plant since the 1960s. In this
study, whole P. niruri plants were collected from
Gulangyu Islet, Fujian province, China, in October
2006 and identified by Professor Yong-Tian Zhang,
Fujian Institute of Subtropical Botany, China. A vou-
cher specimen (20061026) was deposited at Xiamen
Overseas Subtropical Plant Introduction Garden,
China. P. niruri L. is a popular folk medicine for treat-
ing nephritic, urocystic, gastrointestinal, and hepatic
infections. It has traditionally been used in antiviral,
antioxidant, anti-inflammatory, and antidiabetic trea-
tments as well as for radiation protection. Our recent
work identified that Corilagin is a major active com-
pound from P. niruri L. extracts; it is effective in
retarding the growth of hepatocarcinoma cells [unpub-
lished data, Ming et al.].
There has been little research on the effect of
Corilagin on cancer; much of the current research
on Corilagin focuses on its use as an antiviral, hypo-
lipemic, hypotensive and anticoagulation agent [2,3].
A study from Hau DK et al. showed that Corilagin
is considerably effective at retarding the in vivo
growth of xenografted Hep3B hepatocellular carcin-
oma cells [4]; however, there are few reports on the
pharmacology and molecular mechanism of Corila-
gin. When screening plant extracts for TNF-α inhibi-
tors, Okabe et al. [5] and Fujiki et al. [6] found that
Corilagin could significantly inhibit the secretion of
TNF-α.
In this study, we investigated the effect of Corila-
gin on ovarian cancer cells both in vitro and in vivo.
We further explored the intracellular mechanisms
involving Corilagin in multiple signaling pathways
and in inflammatory factor secretion.Methods
Cell culture and reagents
The human ovarian cancer cell lines SKOv3ip and Hey
were obtained from the M. D. Anderson Cancer Center
(Houston, TX, U.S.A.). HO8910PM, a highly metastatic
ovarian cancer cell line [7], was obtained from the Chinese
Academy of Sciences (Shanghai, China). These cell lines
were cultured in DMEM or RPMI 1640 medium supple-
mented with 10% fetal bovine serum. To study the cor-
relation of Snail and TGF-β, we transfected the Snail
expression vector into HO8910PM cells, thereby produ-
cing a stable Snail-expressing cell line, which was cultured
in RPMI 1640 medium supplemented with 10% fetal
bovine serum and 400 μg/ml of G418. Nonmalignant
ovarian surface epithelial (OSE) cells were obtained by
lightly scraping the ovarian epithelial surface, followed by
culture in medium 199:105 supplemented with 15% fetal
bovine serum and 10 ng/ml EGF (Sigma, St. Louis, MO),
as previously described [8]. All samples were obtained with
the patient’s informed consent using protocols and proce-
dures approved by the Institutional Review Board at the
Obstetrics and Gynecology Hospital of Fudan University.
The antibodies against pAKT, AKT, pERK, ERK and Snail
and the Cell Cycle Regulation Antibody Sampler Kit II were
purchased from Cell Signaling Technology (Danvers, MA),
and an anti-GAPDH antibody was purchased from Kang
Chen Bio Co. (Shanghai, China). TGF-β1 was purchased
from Sigma.
Extraction and purification of corilagin
Corilagin was extracted and purified by the Xiamen
Overseas Chinese Subtropical Plant Introduction Garden.
Dried, whole Phyllanthus niruri L. herb was extracted
three times with ethanol, then with n-hexane, trichloro-
methane ethyl acetate, and n-butanol successively. The
n-butanol fraction was subjected to Medium Pressure
Liquid Chromatography (MPLC) using 5% (v/v) acetone
for washes and 15% (v/v) acetone for elution. The fraction
obtained from the 15% acetone elution was subjected to a
polyamide column using 15% (v/v) ethanol to wash, then
25% (v/v) ethanol to elute. The fraction obtained from the
25% ethanol elution was subjected to a Sephadex LH-20
column to yield Corilagin. The purity of Corilagin reached
98.7%, which was confirmed by High Performance Liquid
Chromatography (HPLC) (Figure 1).
Cell proliferation assay
Sulforhodamine B (SRB) was used to detect the effect of
drugs on the proliferation of ovarian cancer cell lines and
OSE cells. Cancer cells (1.5-2.0×103 cells per well in
100 μl medium) and OSE cells (3.0×103 cells per well in
100 μl medium) were seeded in 96-well plates and incu-
bated with Corilagin (0, 8, 16, 24, 32, or 40 μM for the
cancer cells and 0, 60, 120, 240, or 480 μM for the OSE
Figure 1 (A) A diagram of the structure of Corilagin. (B) HPLC confirmation of the purity of Corilagin.
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After 72 hours, 50 μl of 30% trichloroacetic acid was
added and incubated for 60 min at 4C. After washing
and drying the plate, 100 μl of 0.4% SRB was added for
30 min. The plates were rinsed with 0.1% acetic acid and
air-dried, after which 100 μl of Tris base (10 mM/L) was
added, and the plates were shaken for 5 min. The SRB
value was measured at a wavelength of 490 nm. The
experiment was performed in quintuplicate and repeated
three times.
Cell cycle analysis
SKOv3ip and Hey cells were seeded in 60-mm plates
(1–2×105/plate) and incubated with Corilagin (20–40 μM)
or DMSO as a control the next day. Control and treated
cells were trypsinized at 24 or 48 hours after treatment,
collected in PBS and fixed on ice, followed by washing with
70% cold ethanol. After treatment with 10 μg/ml RNase,
cells were stained with 50 μg/ml propidium iodide
(PI, Sigma) for 15 min at room temperature in preparation
for cell cycle analysis. Stained cells were analyzed by flow
cytometry (FACS Calibur) (BD, Franklin Lakes, NJ). The
cell cycle information was analyzed using ModFit3.0
software.
Apoptosis analysis
Hey cells were seeded in a 60-mm dish (1–2×105/dish)
and incubated with Corilagin (20–40 μM) or DMSO as a
control. Control and treated cells were trypsinized at 24
and 48 hours, collected in PBS and stained with Annexin
V and PI according to the manufacturer’s instructions
for the Vybrant W Apoptosis Assay Kit (Invitrogen). The
stained cells were analyzed by flow cytometry.
Reverse phase protein array (RPPA) analysis
Untreated and Corilagin-treated HO8910PM cells were
used for RPPA analysis at The University of Texas, M.D.
Anderson Cancer Center RPPA Core Facility. We followed
the methods described at the following web address: http://
www.mdanderson.org/education-and-research/resources-for-professionals/scientific-resources/core-facilities-and-
services/functional-proteomics-rppa-core/index.html.Western blot analysis
SKOv3ip cells and Hey cells were seeded in 60-mm plates
(1–2×105/plate) and incubated with Corilagin (20–40 μM)
or DMSO, as a control, for 24, 48 or 72 hours. Cell lysates
were harvested with lysis buffer (1% Triton X-100, 50 mM
Hepes, pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM
EGTA, 100 mM NaF, 10 mM NaPPi, and 10% glycerol, to
which 1 mM PMSF, 1 mM Na3VO4, and 1X protease
inhibitor were added before use). HO8910PM-snail cells
were seeded in a 60-mm plate and treated with TGF-β1
alone or in combination with Corilagin; DMSO was used
as the control.
Proteins from total cell lysates were separated using a
10-15% SDS-PAGE gel and transferred to PVDF mem-
branes (Millipore, Billerica, MA). The membranes were
blocked, washed and incubated with specific primary
antibodies. The primary antibody incubation was fol-
lowed by incubation with HRP-conjugated secondary
antibodies. The bands were detected with an enhanced
chemiluminescence assay (PerkinElmer, Waltham, MA).ELISA
Various ovarian cancer cell lines were seeded in 60-mm
plates (1-3×105/plate) and incubated with Corilagin (20,
40, or 80 μM) or DMSO. Culture supernatants were
harvested after 1, 2, and 3 days to measure the concen-
tration of TGF-β1. Hey cells (2.0×103 cells per well in
100 μl of medium) were seeded in 96-well plates and
incubated with Corilagin (40 μM), Paclitaxel (40 nM), or
DMSO the next day. Culture supernatants were
harvested at 48 h to measure the concentration of TGF-
β1. SRB was used to detect the effects of Corilagin and
Paclitaxel on the proliferation of ovarian cancer cells.
The concentration of TGF-β1 was measured by ELISA
according to the manufacturer’s instructions (Shanghai
ExCell Biology, Inc., Shanghai, China).
Figure 2 Corilagin inhibits the proliferation of ovarian cancer
cells but not normal OSE cells. Hey and OSE01 cells were treated
with different concentrations of Corilagin for 72 hours. The growth
curve was measured by SRB assay repeated three times.
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All animal experiments were carried out in accor-
dance with an animal protocol approved by the Insti-
tutional Animal Care and Use Committee of the
Shanghai Tumor Institute. The effect of Corilagin on
the in vivo growth of ovarian cancer xenograft
tumors was evaluated using xenografts of the human
ovarian cancer cell line SKOv3ip in Balb/c nu/nuFigure 3 Corilagin inhibits the growth of SKOv3ip xenograft tumors.
in each group). (B) Xenograft tumor volume measurements during treatme
by volume measurement during treatment. (D) Final xenograft tumor volummice. The SKOv3ip cells (1.5 × 106) were injected
subcutaneously. Tumors were measured twice a
week, and tumor volumes were calculated using the
formula TV = (L × W2)/2, where L represents the
longer diameter and W represents the shorter diam-
eter. When palpable tumors had grown to a diameter
of 0.3-0.5 cm, the mice were divided into four groups
of six to eight, and each group received an intraperi-
toneal injection of either DMSO (as a control) or 5,
10, or 15 mg/kg of Corilagin. The doses of Corilagin
used were in reference to the animal experiments of
Hau DK’s group [4]. The mice were treated three
times per week for four weeks and were then
sacrificed.
Statistical analysis
All data were subjected to statistical analysis and
were reported as the mean ± standard deviation. The
criterion for statistical significance was taken as
P<0.05 using a two-tailed t-test and the count data
were tested using chi-square criterion comparing the
parameters frequency of parameters. The analyses
were performed using SPSS 15.0 software.(A) Mouse weight measurements during treatment (six to eight mice
nt (*P<0.05 compared with control). (C) Xenograft tumor growth curve
es (*P<0.05 compared with control).
Table 1 Corilagin induces G2/M cell cycle arrest in Hey and SKOv3ip cells
G0/G1 (%) S (%) G2/M (%)
Cell line Control Corilagin Control Corilagin Control Corilagin
Hey 1st assay 60 38 21 34 19 28
2nd assay 55 50 26 29 19 21
SKOv3ip 1st assay 64 47 20 20 16 33
2nd assay 63 54 24 19 13 27
Figure 4 Corilagin induces G2/M cell cycle arrest and inhibits cell cycle-related proteins. (A) Hey and SKOv3ip cells were treated with
Corilagin (40 μM). Cell cycle analyses were performed using flow cytometry after two days of treatment. Cells without treatment were used as the
control. The experiments were repeated twice (see Table 1), with the figure depicting a representative experiment. (B) Hey and SKOv3ip cells
were treated with Corilagin for two days at different concentrations (lower, 20 μM, and higher, 40 μM). Cells without treatment were used as the
control. Cyclin B1, p-Weel, p-cdc2 and Myt1 levels were analyzed by Western blotting.
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Figure 5 Corilagin induces cell apoptosis. Hey cells were treated with Corilagin at different concentrations (lower, 20 μM, and higher, 40 μM);
apoptosis was evaluated by flow cytometry at 24 hours (top row) and 48 hours (bottom row) after treatment. Cells without treatment were used
as the control. UR: upper-right corner of flow cytometric analysis, LR: lower-right corner of flow cytometric analysis.
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Corilagin inhibits the growth of ovarian cancer cell lines
in vitro and in vivo
Ovarian cancer cell lines (Hey, SKOv3ip, and HO8910PM)
and normal OSE cells (OSE01, OSE02, and OSE03) were
used to examine the effects of Corilagin in cell culture.
Corilagin demonstrated clear inhibition of ovarian cancer
cell growth (the IC50s were 27 μM for SKOv3ip and
28 μM for Hey cells) but had much lower cytotoxicity in
normal OSE cells, with IC50s of approximately 160 μM
(148 μM for OSE01, 176 μM for OSE02 and 192 μM for
OSE03) (Figure 2).
To determine if Corilagin had the same effect in vivo,
Corilagin was delivered by intraperitoneal injection into
mice bearing SKOv3ip xenografts. Mouse weight mea-
surements were not significantly different between the
control and Corilagin-treated groups (Figure 3A), but
xenograft tumor size was reduced significantly (P<0.05) in
the Corilagin-treated groups, especially in the 15 mg/kg
group, compared with the control group (Figure 3B, C).The final volume measurement of the xenograft tumors
(Figure 3D) also showed that the 15 mg/kg Corilagin
treatment statistically inhibited tumor growth (P<0.05).
Thus, the growth of the SKOv3ip xenografts was signifi-
cantly inhibited by Corilagin treatment.Corilagin induces G2 cell cycle arrest and apoptosis
When Hey and SKOv3ip cells were treated with Cori-
lagin, the frequency of cells in the G2/M phase was
markedly increased compared with the untreated cells
(Table 1, Figure 4A). Furthermore, analyses of cell
cycle-related proteins suggest that Corilagin arrested
ovarian cancer cells in the G2/M phase by down-
regulating the expression levels of Cyclin B1, Myt1,
Phospho-Weel (p-Weel) and Phospho-cdc2 (p-cdc2)
(Figure 4B). Corilagin also induced apoptosis in the
ovarian cancer cells. Figure 5 shows that the number
of apoptotic Hey cells was significantly increased after
48 h of treatment with Corilagin.
Figure 6 Corilagin inhibits the secretion of TGF-β1 in ovarian cancer cells. (A) The TGF-β1 secretion of three ovarian cancer cell lines,
HO8910PM, SKOv3ip and Hey, was inhibited by Corilagin in a dose-dependent manner. The experiments were repeated three times (*P<0.05 or
**P<0.01, compared with the untreated control cells). (B) Both Corilagin (40 μM) and Paclitaxel (40 nM) inhibited Hey cell growth. Experiments
were repeated three times (*P<0.05 compared with untreated control cells). (C) Corilagin, but not Paclitaxel, inhibited the secretion of TGF-β1 in
Hey cells. Experiments were repeated three times (*P<0.05 compared with untreated control cells).
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Corilagin was reported to inhibit TNF-α secretion [5,6],
but TNF-α was unable to be detected by regular ELISA
from the culture supernatants of ovarian cancer cells.
We tested whether Corilagin could inhibit additional in-
flammatory factors. Previously, a high concentration of
TGF-β was detected in ascites, blood and other bodily
fluids of ovarian cancer patients. Using an ELISA, we
also found that most ovarian cancer cell lines secrete
TGF-β1 into cell culture supernatants, and this secretion
increased as the growth rate increased. In this study, we
found that TGF-β1 secretion dramatically declined in a
dose-dependent manner in the culture supernatants of
Hey, SKOv3ip and HO8910PM cells (Figure 6A). Com-
paring Corilagin with Paclitaxel, a known chemotherapeutic
drug for ovarian cancer, Corilagin inhibited both cell
growth and the secretion of TGF-β1, while Paclitaxel only
inhibited cell growth (Figure 6B, C).
Corilagin blocks multiple signaling pathways
To understand the anti-tumor mechanisms of Corilagin,
we performed a RPPA analysis of untreated and Corila-
gin (at lower, 20 μM, and higher, 40 μM, concentra-
tions)-treated HO8910PM cells. Figure 7A presents a
small portion of the results. The RPPA analysis indicated
that several signaling pathways were down-regulated
after Corilagin treatment. Western blotting was used to
verify these candidates in the HO8910PM, Hey andSKOv3ip cell lines, and we found that Corilagin blocked
the activation of multiple signaling cascades, such as
pAKT and pERK (Figure 7B, C). Additional candidates
from the RPPA analysis will need to be verified. We also
observed that Myt1 was down-regulated following treat-
ment with Corilagin either with or without EGF
(Figure 7B). We tested two purified extracts from Phyl-
lanthus niruri L., ethyl brevifolin carboxylate and Corilagin,
but only Corilagin inhibited AKT signaling (Figure 7C). In
HO8910PM-Snail cells, Corilagin significantly inhibited
pERK and blocked the stimulatory effect of TGF-β on
pERK. Corilagin treatment also blocked the upregulation of
Snail expression by TGF-β. As an inhibitor of pERK, U0126
could inhibit pERK but had no effect on the expression of
Snail (Figure 7D), suggesting that the TGF-β-mediated
stimulation of Snail does not occur through pERK.
Figure 7E shows that Corilagin blocked pSmad2 with or
without TGF-β induction, although SKOv3ip cells
were more sensitive than HO8910PM cells to the
TGF-β-mediated induction of pSmad2. As a result,
Corilagin could be involved in both canonical (Smad)
and non-canonical (AKT/ERK) pathways. Figure 8
summarizes the possible signaling pathways that
might be affected by Corilagin.
Discussion
Herbal medicines are currently attracting attention as
potential cancer therapeutics and preventive agents.
Figure 7 Corilagin blocks multiple signaling pathways. (A) RPPA analysis of untreated and Corilagin (at lower, 20 μM, and higher, 40 μM,
concentrations)-treated HO8910PM cells. Figure presents a small portion of the results. (B) Corilagin inhibited pAKT, Myt1 and pERK in Hey,
SKOv3ip, or HO8910PM cells. Non-phosphorylated AKT, GAPDH and non-phosphorylated ERK were used as the loading controls. (C) Corilagin
(as compound C) inhibited AKT signaling in Hey cells, but ethyl brevifolin carboxylate (as compound A) did not. Non-phosphorylated AKT was
used as the loading control. (D) Corilagin inhibited the expression of pERK and Snail in HO8910PM-Snail cells and the TGF-β-mediated stimulation
of pERK and Snail. Non-phosphorylated ERK was used as the loading control. U126, a pERK inhibitor, was used as the positive control. (E) Corilagin
inhibited TGF-β-mediated pSmad2 expression in HO8910PM and SKOv3ip cells. Non-phosphorylated Smad2 was used as the loading control.
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that has been used as a hepatoprotective, antiviral, anti-
bacterial, analgesic, antispasmodic and antidiabetic
medicine; however, there are few reports describing its
anti-tumor activity. Our group isolated components of
Phyllanthus niruri L. by chromatographic fractionation
and mass spectrometry. Of the two major isolated com-
ponents (ethyl brevifolin carboxylate and Corilagin),
Corilagin demonstrated better anti-tumor potential and
lower toxicity in normal cells [unpublished data, Ming et
al.]. Corilagin is a gallotannin that has been identified in
several plants, including Phyllanthus niruri L. [9].
Corilagin has been shown to exhibit versatile medicinal
activity including anti-inflammatory effects as well as
hepato-protective activity [2,10,11]. Recently, an anti-tumor
effect on hepatocellular carcinoma was reported [4];
however, the anti-tumor mechanism is still unclear.In this study, we confirmed the antitumor effect of
Corilagin on ovarian cancer cells and further investi-
gated the mechanism of this effect. Corilagin induced
cell cycle arrest at the G2/M stage and enhanced apop-
tosis in ovarian cancer cells. Cyclin B1, Myt1, Phospho-
cdc2 and Phospho-Weel were down-regulated after
Corilagin treatment. Importantly, we found that Corilagin
inhibited TGF-β secretion into the culture supernatant of
all tested ovarian cancer cell lines and blocked the
stabilization of Snail induced by TGF-β. The reduction of
TGF-β secretion was specific to Corilagin treatment;
Corilagin also targeted TGF-β-related signaling molecules,
such as pAKT, pERK and pSmads. Other natural products,
such as genistein and curcumin, can also alter the
TGF-β pathway. Both of these agents can abrogate
the enhancement of u-PA levels induced by TGF-β1 and
also inhibit the TGF-β1-induced synthesis of fibronectin
Figure 8 A diagram of the pathways potentially affected by Corilagin.
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tial to be effective in the treatment of cancer.
G2/M checkpoint-based anti-cancer strategies have fo-
cused on targeting and inactivating the G2/M check-
point, thus forcing the cancer cells into mitosis with
increased DNA damage and finally into mitotic catastro-
phe and cell death. The Cyclin B/cdc2 complex performs
an important function in controlling the G2/M phase by
rapidly phosphorylating the target protein to induce pro-
gression into the M phase [13,14]. The phosphorylation
and dephosphorylation of specific amino acids in cdc2
are responsible for the control of G2/M cell cycle pro-
gression by the Cyclin B1/cdc2 complex [13,14]. More
specifically, in the G2 phase, cdc2 is phosphorylated at
Thr14 and Tyr15 by the protein kinases Myt1 and
Wee1, thereby converting it into an inactive precursor.
Consistent with these reports, in the present study, we
observed that Corilagin decreases the protein level of
Cyclin B1, p-cdc2 (Tyr15) in both Hey and SKOv3ip
cells, which might be the molecular mechanism respon-
sible for Corilagin’s efficacy in inducing G2/M arrest.
We also observed down-regulation of p-Wee1 (Ser642)
and Myt1 in Hey and SKOv3ip cells, indicating that the
efficacy of Corilagin in inducing G2/M arrest in ovarian
cancer cells is possibly due to the down-regulation of
cdc2 and Cyclin B1 through Wee1 and Myt1 regulation.
Akt is suggested to function as a G2/M initiator. The
activity of PI3K/Akt is required at multiple points during
the cell cycle. Downstream functions of the PI3K/Akt
pathway during G2/M transitions may include inhibition
of the Chk1 G2 checkpoint protein or activation of
cdc25C, which promotes cdc2 activation and entry into
mitosis in primary oocytes from the starfish Asterina
pectinifera [15]. Akt was reported to inhibit Myt1through Akt-dependent phosphorylation and down-
regulation at the G2/M transition [16]. In the present
study, we observed that Corilagin inhibited both pAKT
(Ser473) and Myt1 expression in Hey and SKOv3ip cells
after stimulation with EGF, suggesting that the inhibition
of Akt/Myt1 also contributes to the G2/M arrest result-
ing from Corilagin treatment. Further studies will be
required to support these assumptions and to determine
the role of upstream events, such as Chk1 and Chk2, in
ovarian cancer cell responses to Corilagin.
Corilagin has been reported as a TNF-α-releasing in-
hibitor in inflammatory scenarios [5,6]. In this study, we
observed that the secretion of TGF-β was inhibited by
Corilagin in a dose-dependent manner in all ovarian
cancer cells evaluated, indicating that Corilagin also dis-
turbed the expression and efficacy of TGF-β. Our results
further demonstrated that Corilagin not only targets the
classical Smad pathway via pSmad2 but also down-
regulates MAPK signaling. The thing that most intrigued
us is that Corilagin treatment induced a dramatic decline
in the expression of the Snail protein, especially at
higher doses, which indicates that Corilagin not only
exerts its effects on cell cycle control but also contri-
butes to epithelial-mesenchymal transition (EMT) in
ovarian cancer.
As with all cancer cells, ovarian cancer cells undergo
an EMT to disseminate within the intraperitoneal cavity
or metastasize to distant sites [17]. TGF-β signaling
plays a critical role in ovarian cancer EMT and metasta-
sis. Ovarian cancer is thought to arise from normal ova-
rian surface epithelium (OSE). TGF-β has been shown
to inhibit human OSE proliferation and induce apop-
tosis, which may prevent the over-proliferation of cells
during a normal ovulatory cycle [18]. Although TGF-β
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feration in the early stages of tumor development, it can
also promote metastasis in various cancer models
[19,20]. It appears that at later stages, cancer cells protect
themselves and tend to acquire increasing resistance to
TGF-β growth inhibitory signals, which is an important
reason for the shift of TGF-β from tumor suppressor to
tumor promoter [21]. Much remains to be elucidated
about how TGF-β contributes to ovarian cancer progres-
sion, particularly in the regulation of EMT. A high
concentration of TGF-β has been detected in ascites,
blood and other bodily fluids of ovarian cancer patients
[22]. When ovarian cancer cells were cultured, various
TGF-βs, including TGF-β1, TGF-β2 and TGF-β3, induced
pro-matrix metalloproteinase (MMP) secretion, the loss of
cell-cell junctions, down-regulation of E-cadherin, up-
regulation of N-cadherin, and the acquisition of a fibro-
blastoid phenotype, all of which are consistent with EMT
[23-25]. In addition, our recent studies identified that
TGF-β is the most important inflammatory factor in
ovarian cancer. TGF-β stabilizes the protein level of Snail,
an inducer of EMT, and further enhances Snail expression
when combined with other inflammatory factors (Jin et al.
unpublished data). However, how Corilagin has this effect
on TGF-β and thus undermines the stability of Snail still
needs to be elucidated.
TGF-β binds to type I (ThRI) and type II (ThRII)
receptors. Upon ligand binding to ThRII, ThRI is acti-
vated and phosphorylates the receptor-regulated Smads.
The phosphorylated receptor-regulated Smads then bind
to the co-Smad, Smad4, and translocate to the nucleus
to modulate gene expression. TGF-β also initiates Smad-
independent pathways, including those mediated by the
mitogen-activated protein kinase family members
(TAK1, extracellular signal-regulated kinase, p38, and
c-Jun-NH2-kinase) and phosphatidylinositol 3-kinase
[26]. In this study, we found that Corilagin not only
inhibits the secretion of TGF-β but also blocks the
TGF-β-related signaling proteins pSmads, pAKT, and
pERK (Figure 8). Our research provides evidence that
TGF-β/Smad/AKT/ERK signaling is the target of Corilagin
and that this herbal medicine could be an effective ovarian
cancer therapeutic agent.
Conclusions
Corilagin is a major active component with anti-tumor
activity from P. niruri L. Our results indicated that Cori-
lagin distinctly inhibited the growth of ovarian cancer
cells in vitro and in vivo, while displaying low toxicity
against normal cells. More interestingly, Corilagin inhib-
ited TGF-β secretion and blocked the stabilization of
Snail that is induced by TGF-β; Corilagin blocked the
activation of both canonical Smad and non-canonical
ERK/AKT pathways. Corilagin, therefore, acts as a natural,effective therapeutic agent against the growth of ovarian
cancer cells via targeted action on the TGF-β/AKT/ERK/
Smad signaling pathways.
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